BACKGROUND: Breast cancer is an important cause of cancerrelated death in women. In this pathological condition, arginase plays a role by providing ornithine as a substrate for the biosynthesis of polyamines which are important in tumor progression. The aim of this work was to determine the arginase activity in the plasma and tumors of patients with breast cancer; also, we investigated the relationship between this activity and the presence of the estrogen receptor. PATIENTS AND METHODS: We evaluated the plasma arginase activity levels in 80 women with breast cancer and 42 healthy control subjects. We also measured the arginase levels in 42 breast cancer biopsies and 42 control tissues. RESULTS: The mean activity of arginase in plasma was higher in breast cancer patients (0.78 nM/min/mg protein ± 0.04; p = 0.001) than in healthy volunteers (0.53 nM/ min/mg protein ± 0.04); however, this difference was indicative of patients in the advanced stages of the disease (n = 38, stage III; p < 0.0001). In addition, we did not find a relationship between the estrogen receptor and arginase activity. CONCLUSION: Our results show a higher arginase activity in the plasma of patients in the advanced stages of the disease, suggesting that arginase activity could serve as a possible biological marker of breast cancer progression.
BACKGROUND:Breast cancer is an important cause of cancerrelated death in women. In this pathological condition, arginase plays a role by providing ornithine as a substrate for the biosynthesis of polyamines which are important in tumor progression. The aim of this work was to determine the arginase activity in the plasma and tumors of patients with breast cancer; also, we investigated the relationship between this activity and the presence of the estrogen receptor. PATIENTS AND METHODS: We evaluated the plasma arginase activity levels in 80 women with breast cancer and 42 healthy control subjects. We also measured the arginase levels in 42 breast cancer biopsies and 42 control tissues. RESULTS: The mean activity of arginase in plasma was higher in breast cancerpatients (0.78 nM/min/mg protein ± 0.04; p = 0.001) than in healthy volunteers (0.53 nM/ min/mg protein ± 0.04); however, this difference was indicative of patients in the advanced stages of the disease (n = 38, stage III; p < 0.0001). In addition, we did not find a relationship between the estrogen receptor and arginase activity. CONCLUSION: Our results show a higher arginase activity in the plasma of patients in the advanced stages of the disease, suggesting that arginase activity could serve as a possible biological marker of breast cancer progression.
Authors: Xinming Su; Yalin Xu; Gregory C Fox; Jingyu Xiang; Kristin A Kwakwa; Jennifer L Davis; Jad I Belle; Wen-Chih Lee; Wing H Wong; Francesca Fontana; Leonel F Hernandez-Aya; Takayuki Kobayashi; Helen M Tomasson; Junyi Su; Suzanne J Bakewell; Sheila A Stewart; Christopher Egbulefu; Partha Karmakar; Melisa A Meyer; Deborah J Veis; David G DeNardo; Gregory M Lanza; Samuel Achilefu; Katherine N Weilbaecher Journal: J Clin Invest Date: 2021-10-15 Impact factor: 14.808